CN103751605A - 一种治疗肝硬化的草药 - Google Patents
一种治疗肝硬化的草药 Download PDFInfo
- Publication number
- CN103751605A CN103751605A CN201410004160.3A CN201410004160A CN103751605A CN 103751605 A CN103751605 A CN 103751605A CN 201410004160 A CN201410004160 A CN 201410004160A CN 103751605 A CN103751605 A CN 103751605A
- Authority
- CN
- China
- Prior art keywords
- herba
- liver cirrhosis
- liver
- herbal medicine
- triquetri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 25
- 241000411851 herbal medicine Species 0.000 title abstract 4
- 241000505911 Tadehagi Species 0.000 claims abstract description 7
- 235000008216 herbs Nutrition 0.000 claims description 12
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 6
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 6
- 241001330002 Bambuseae Species 0.000 claims description 6
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 6
- 239000011425 bamboo Substances 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 206010003445 Ascites Diseases 0.000 abstract description 5
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000018109 developmental process Effects 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 244000305707 Ananas bracteatus Species 0.000 abstract 1
- 235000016089 Ananas bracteatus Nutrition 0.000 abstract 1
- 241000335156 Bambusa remotiflora Species 0.000 abstract 1
- 244000104272 Bidens pilosa Species 0.000 abstract 1
- 235000010662 Bidens pilosa Nutrition 0.000 abstract 1
- 241000508725 Elymus repens Species 0.000 abstract 1
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 240000003146 Lobelia chinensis Species 0.000 abstract 1
- 240000001519 Verbena officinalis Species 0.000 abstract 1
- 235000018718 Verbena officinalis Nutrition 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 231100000832 liver cell necrosis Toxicity 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000036178 pleiotropy Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开的一种治疗肝硬化的草药，由半边莲、香白芷、玉米须、野菠萝、鬼针草、茅根、葫芦茶、甲竹菜、马鞭草、仙鹤草10昧药材制备而成。疗效好、无毒副作用，能治标治本，治愈除根，克服现有技术的不足。具有独特的多向性和广泛的适应症，对提高和调整机体免疫功能，抑制肝内纤维素增生，改善肝内血液循环，防止肝细胞坏死，促进肝细胞的修复和再生，使肿大的肝脾回缩，腹水中止发展和消除有很好的作用。
Description
技术领域
本发明涉及肝硬化治疗，尤其是涉及一种治疗肝硬化的草药。
背景技术
肝硬化是临床上的常见多发病，是致发肝细胞癌变的主要因素。西医认为：引起肝硬化的病因很多，其病理改变及临床表现也有差异。同一病因可发展为不同病理类型的肝硬化；而同一病理类型的肝硬化又可由多种病因演变而成，故迄今尚无根据病因结合其病理形态在理论和临床实践上进行统一分类。在我国病毒性肝炎、慢性酒精中毒和血吸虫病是最常见的肝硬化致病因素。肝硬化的起病与病程发展一般均较缓慢，可隐伏数十年之久。肝功能代偿期症状较轻，常缺乏特异性，以疲倦乏力、食欲减退及消化不良为主。可有恶心、厌油、腹部胀气、上腹不适、隐痛及腹泻。失代偿时，全身症状加重，并出现门脉高压症。西药无特效草药治疗，严重者可进行肝移植。而中医学认为此病是由于肝气郁结、气滞血瘀而致的各种肝失调症状。
目前对肝硬化的治疗仍无突破性进展。临床治疗方法以护肝治疗为主，同时结合抗病毒治疗。其共同特点是促进损伤的肝细胞再生，保护肝细胞免于损伤或减轻损伤，起到抗肝细胞坏死和促进肝细胞修复的作用。但现有治疗肝硬化草药大都治标不治本，不能治愈除根。如：肌苷、肝泰乐、白蛋白、细胞能量合剂、复方氨基酸制剂等，对提高肝硬化的治愈率及缓解并发症仍不尽人意，对肝硬化腹水的治疗采取限钠、安体舒通、利尿剂、使用人血白蛋白、纠正水盐等措施其成功率同样不高，作用短暂。且常出现嗜睡、头晕、恶心、呕吐、血压降低等不良反应。
发明内容
本发明的目的是提供一种治疗肝硬化的草药，采用纯中药制备，配方独特，具有清热解毒、燥湿健脾、化瘀通络、软坚散结、平肝止痛、祛瘀生新的功效。疗效好、无毒副作用，能治标治本，治愈除根，克服现有技术的不足。
本发明的目的是这样实现的：
一种治疗肝硬化的草药，其特征在于以半边莲、香白芷、玉米须、野菠萝、鬼针草、茅根、葫芦茶、甲竹菜、马鞭草、仙鹤草10昧药材为原料。
一种治疗肝硬化的草药，其特征在于按重量份比例由半边莲40-50份、香白芷40-50份、玉米须40-50份、野菠萝15-25份、鬼针草15-20份、茅根10-15份、葫芦茶10-15份、甲竹菜10-15份、马鞭草10-15份、仙鹤草15-20份10昧药材混合配制加水按常规煎药方法煎煮取液而成。
本发明公开的一种治疗肝硬化的草药，由半边莲、香白芷、玉米须、野菠萝、鬼针草、茅根、葫芦茶、甲竹菜、马鞭草、仙鹤草10昧药材制备而成。疗效好、无毒副作用，能治标治本，治愈除根，克服现有技术的不足。具有独特的多向性和广泛的适应症，对提高和调整机体免疫功能，抑制肝内纤维素增生，改善肝内血液循环，防止肝细胞坏死，促进肝细胞的修复和再生，使肿大的肝脾回缩，腹水中止发展和消除有很好的作用。
服用方法：患者每天口服2-3次，每次200-300毫升，10天为1疗程。经临床验证，一般服药3月即可康复。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。
实施例：
按重量份比例将半边莲40-50份、香白芷40-50份、玉米须40-50份、野菠萝15-25份、鬼针草15-20份、茅根10-15份、葫芦茶10-15份、甲竹菜10-15份、马鞭草10-15份、仙鹤草15-20份10昧药材混合配制加水按常规煎药方法煎煮取液滤渣即得本发明药液。
临床应用
应用本发明治疗肝硬化时，患者可将制成的药液每天分早中晚口服三次，每次200-300毫升，10天为1疗程。下面是本发明的三个典型病例：
1、李先生，58岁，广西凤山县凤城镇居民，2009年8月确诊为肝硬化、脾大、胆囊炎。在医院用干扰素胸腺酞等药治疗无效，患者症状右肋区扣击痛胀，四肢无力、小便时黄时清，B超显示，肝被膜粗糙，实质回声呈网状增强，分布不均匀，管系紊乱不清。使用本发明实施例草药3个月后症状无，B超显示正常、痊愈。
2、罗先生，49岁，广西凤山县凤城镇某村农民，1994年10月突然感到呕心、呕吐，内容物为鲜血，被县医院确诊为肝硬化，胆囊类脾大引起的大出血，到过许多大医院治疗效果不佳，使用本发明实施例草药3个月后症状无，B超显示正常痊愈。至今未复发。
3、黄先生，52岁，广西凤山县袍里乡某村农民，自述曾患乙肝，1997年12月感到身体不适，经检查发现乙肝转为肝硬化并大量腹水。病人消瘦、腹胀满，下肢浮肿。B超显示：肝脏缩小，肝边呈锯齿状，到过许多大医院就诊，花钱不少病没治好。经发明人用本发明中药治疗，服药1月后复诊，腹部水肿消失，饮食倍增，乏力现象消失。继续服药2个月后到医院复查肝功能，结果明显趋于正常。症状大有好转，使用至第4个月后查B超，肝大小正常，表面光正，肝硬化痊愈，现已逾十六年病人至今未见异常。
Claims (2)
1.一种治疗肝硬化的草药，其特征在于以半边莲、香白芷、玉米须、野菠萝、鬼针草、茅根、葫芦茶、甲竹菜、马鞭草、仙鹤草10昧药材为原料。
2.根据权利要求1所述一种治疗肝硬化的草药，其特征在于按重量份比例由半边莲40-50份、香白芷40-50份、玉米须40-50份、野菠萝15-25份、鬼针草15-20份、茅根10-15份、葫芦茶10-15份、甲竹菜10-15份、马鞭草10-15份、仙鹤草15-20份10昧药材混合配制加水按常规煎药方法煎煮取液而成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410004160.3A CN103751605A (zh) | 2014-01-01 | 2014-01-01 | 一种治疗肝硬化的草药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410004160.3A CN103751605A (zh) | 2014-01-01 | 2014-01-01 | 一种治疗肝硬化的草药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103751605A true CN103751605A (zh) | 2014-04-30 |
Family
ID=50519032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410004160.3A Pending CN103751605A (zh) | 2014-01-01 | 2014-01-01 | 一种治疗肝硬化的草药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751605A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012764A (zh) * | 2015-08-20 | 2015-11-04 | 韦江南 | 一种治疗肝硬化的中药组合物 |
| CN106491749A (zh) * | 2017-01-12 | 2017-03-15 | 青岛大学附属医院 | 用于预防和/或治疗肝纤维化的中药组合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167893A (zh) * | 2007-09-24 | 2008-04-30 | 梁平 | 治疗病毒性肝炎的中药 |
-
2014
- 2014-01-01 CN CN201410004160.3A patent/CN103751605A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167893A (zh) * | 2007-09-24 | 2008-04-30 | 梁平 | 治疗病毒性肝炎的中药 |
Non-Patent Citations (1)
| Title |
|---|
| 程栽芝: "程谦山治疗肝硬化的经验", 《浙江中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012764A (zh) * | 2015-08-20 | 2015-11-04 | 韦江南 | 一种治疗肝硬化的中药组合物 |
| CN106491749A (zh) * | 2017-01-12 | 2017-03-15 | 青岛大学附属医院 | 用于预防和/或治疗肝纤维化的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103316305B (zh) | 一种治疗肝硬化的中药组合物及其制备方法 | |
| CN102579973A (zh) | 一种治疗胆结石的药物 | |
| CN103751605A (zh) | 一种治疗肝硬化的草药 | |
| CN102940798B (zh) | 一种治疗肾病综合征的中药组合物及其制备方法 | |
| CN105494777A (zh) | 一种具有改善肝功能的药茶 | |
| CN104435789A (zh) | 一种治疗肝硬化的药物 | |
| CN103432330A (zh) | 一种治疗肾衰竭的中药及其制备方法 | |
| CN102698150A (zh) | 一种治疗溃疡性结肠炎的内服中药组合物 | |
| CN102302699A (zh) | 一种治疗湿疹的茶 | |
| CN102397431A (zh) | 阑尾炎口服液 | |
| CN103007079B (zh) | 一种治疗痛风的中成药 | |
| CN106075269A (zh) | 一种治疗胃胀气的中药组合物 | |
| CN105477211A (zh) | 一种治疗急性胃肠炎的中药汤剂 | |
| CN103330846A (zh) | 一种治疗肾病综合症的中药 | |
| CN104257908A (zh) | 一种治疗风湿性关节炎的中药制剂及制备方法 | |
| CN103977345A (zh) | 一种治疗甲状腺肿大的中药配方及其制备方法 | |
| CN103611078A (zh) | 一种治疗慢性盆腔炎的中药口服液及其制备方法 | |
| CN104248681A (zh) | 一种治疗风湿关节炎的中药颗粒及其制备方法 | |
| CN104352659A (zh) | 治疗血栓性静脉炎的中药制剂 | |
| CN104107328A (zh) | 一种治疗胃病的中药干膏 | |
| CN103494939A (zh) | 一种治疗老年习惯性便秘的中药 | |
| CN102688373A (zh) | 一种治疗便秘的药物及其制备方法 | |
| CN108066635A (zh) | 一种润肠通便的中药组合物 | |
| CN102670844A (zh) | 乌药消炎丸 | |
| CN104173577A (zh) | 一种治疗风湿关节炎的中药颗粒及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140430 |